IRD - Opus Genetics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

IRD

OPUS GENETICS, INC.

NASDAQ

$3.69

▼ DOWN 4.16% (-0.16)

KEY STATISTICS

Market Cap$304.67 M

52w High$5.81

52w Low$1.22

Dividend Yield—

Frequency—

P/E-2.88

Volume822.21K

Shares Out.82.57M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

George Magrath

COMPENSATION 2026

Salary$598,000

Stock Awards$307,548

Incentive Plan Pay$361,790

All Other Comp.$14,000

Total$1,493,383

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 19, 2015

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$10.00

Target Low$8.00

Target Median$9.00

Target Consensus$9.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$1.86M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2020-11-06	Reverse	1:4
2019-04-12	Reverse	1:12
2017-05-05	Reverse	1:10
2005-05-23	Reverse	1:100

PRICE

$3.69 ▼ DOWN 4.16% (−$0.16)

OVERLAYS

About Opus Genetics, Inc.

https://opusgtx.com ↗

Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company developing therapies for refractive and retinal eye disorders, including Phentolamine Ophthalmic Solution and retinal candidates like APX3330, with several products in Ph...

INDUSTRY

Biotechnology

A PRODUCT OPUS GENETICS, INC. IS KNOWN FOR

OPGx-LCA5

OPGx-LCA5 is an investigational gene therapy using AAV to treat LCA caused by LCA5 mutations, currently in Phase 1/2 trials and progressing toward Phase 3, with RMAT designation from the FDA.